These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

Benzinga Earnings

08/10

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.

The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.

ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.

“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.”

ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.

These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.

Canaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.
Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.

Considering buying ANIP stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2658932749"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658932749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658932749?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658932749","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong>ANI Pharmaceuticals Inc</strong> (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.</p>\n<p>The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.</p>\n<p>ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.</p>\n<p>“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.”</p>\n<p>ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.</p>\n<p>These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.</li>\n<li>Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.</li>\n</ul>\n<p><strong>Considering buying ANIP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"323\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-1024x323.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-1024x323.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-300x95.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-768x242.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250.png 1151w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2026-08-10 22:39</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>ANI Pharmaceuticals Inc</strong> (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.</p>\n<p>The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.</p>\n<p>ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.</p>\n<p>“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI. “Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.”</p>\n<p>ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.</p>\n<p>These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.</li>\n<li>Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.</li>\n</ul>\n<p><strong>Considering buying ANIP stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"323\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-1024x323.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-1024x323.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-300x95.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250-768x242.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/10103719/image-250.png 1151w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61077973/these-analysts-slash-their-forecasts-on-ani-pharmaceuticals-after-q2-results","article_id":"2658932749","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658932749","pubTimestamp":1786372754,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"这些分析师在第二季度业绩公布后大幅下调了对 ANI Pharmaceuticals 的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1.5},"content_text":"ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.\nThe company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.\nANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.\n「In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,」 said Nikhil Lalwani, President and CEO of ANI. 「Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel’s sizable multi-year growth opportunity.」\nANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.\nThese analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.\n\nCanaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90.\nGuggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.\n\nConsidering buying ANIP stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}